Ito Yuta, Shimono Joji, Kawamoto Keisuke, Hatanaka Kanako C, Kogure Yasunori, Tabata Mariko, Saito Yuki, Mizuno Kota, Horie Sara, Mizukami Yosuke, Koya Junji, Murakami Koichi, Teshima Takanori, Hatanaka Yutaka, Chiba Kenichi, Okada Ai, Shiraishi Yuichi, Miyoshi Hiroaki, Matsuno Yoshihiro, Ohshima Koichi, Kataoka Keisuke, Nakagawa Masao
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Leukemia. 2025 May 2. doi: 10.1038/s41375-025-02631-5.
Nodal T follicular helper cell lymphoma (nTFHL) exhibits unique immunophenotypes and somatic alterations, while the prognostic value of these alterations remains unclear. By analyzing 173 nTFHL cases, we identified 36 driver genes, including 4 novel ones (TET3, HLA-C, NRAS, and KLF2). Then, we classified nTFHL cases into four molecular subgroups by major driver alterations. TR-I (+) and TR-I (-) were characterized by TET2 and/or RHOA mutations with and without IDH2 mutations; AC53 by TP53 and/or CDKN2A alterations and aneuploidy; and NSD with no subgroup-defining alterations (namely without any of the above alterations). AC53 exhibited the worst survival, while NSD, particularly those lacking driver alterations, showed the best prognosis. nTFHL had a better prognosis than peripheral T-cell lymphoma, not otherwise specified, when TP53 and/or CDKN2A alterations were absent. Multivariable analyses showed that AC53, the presence of driver alterations, and international prognostic index high-risk were independently associated with worse survival. Finally, we developed a simple prognostic index (mTFHL-PI), which classified patients into three risk categories with a median OS of 181, 67, and 20 months, respectively. Our study identifies novel prognostic factors, namely TP53 and/or CDKN2A alterations and the presence of driver alterations, demonstrating the clinical relevance of molecular classification in nTFHL.
淋巴结T滤泡辅助细胞淋巴瘤(nTFHL)具有独特的免疫表型和体细胞改变,而这些改变的预后价值仍不清楚。通过分析173例nTFHL病例,我们鉴定出36个驱动基因,包括4个新基因(TET3、HLA-C、NRAS和KLF2)。然后,我们根据主要驱动改变将nTFHL病例分为四个分子亚组。TR-I(+)和TR-I(-)的特征分别是伴有和不伴有IDH2突变的TET2和/或RHOA突变;AC53的特征是TP53和/或CDKN2A改变及非整倍体;而NSD没有定义亚组的改变(即没有上述任何一种改变)。AC53的生存率最差,而NSD,尤其是那些没有驱动改变的病例,预后最好。当不存在TP53和/或CDKN2A改变时,nTFHL的预后比未另行指定的外周T细胞淋巴瘤要好。多变量分析显示,AC53、驱动改变的存在以及国际预后指数高危与较差的生存率独立相关。最后,我们开发了一种简单的预后指数(mTFHL-PI),它将患者分为三个风险类别,中位总生存期分别为181个月、67个月和20个月。我们的研究确定了新的预后因素,即TP53和/或CDKN2A改变以及驱动改变的存在,证明了nTFHL分子分类的临床相关性。